Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Lung
Study Phase
Phase 2B
Study Completion Date
2011
NCT01439568Uploaded 01-23-2019
Available for Download
PDS UID: LungSm_EliLill_2011_287
N/A
Provider Information
Provider Data DescriptionThe primary objective was to compare the progression-free survival (PFS) between treatment arms. Secondary objectives were OS, overall response rate (ORR), duration of overall response (DOR), and safety.
SponsorEli Lilly
Data ProviderEli Lilly
Partial set or SubsetOriginal Data
Patients in dataset92
# of Patients Control46
# of Patients Experimental48
DOIhttps://doi.org/10.34949/bscb-ga21
CDISC StandardSDTM
Study ArmsBoth comparator and experimental arm data
Clinical Trials.gov Information
Brief SummaryN/A
ConditionsN/A
Intervention TypeChemotherapy
Drug(s)N/A
Total EnrolledN/A
RandomizationN/A
Blinding MethodN/A
Arms InterventionN/A
Secondary IDN/A
PubMed (PMID)N/A
Collaborator(s)N/A
Region(s)N/A
Age RangeN/A
Files:
PROTOCOLLilly Protocol LY2510924_CXAC.pdf
CRFLilly CRF LY2510924_CXAC.pdf
DATA DICTIONARYProc Contents Data Dictionary.docx
DATA (COMPARATOR ARM)Lilly data LY2510924_CXAC.zip
© 2023 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use